Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects

• Published in: Clinical pharmacology and therapeutics Vol. 90; no. 2; p. 287
• Main Authors: Simon, T, Bhatt, D L, Bergougnan, L, Farenc, C, Pearson, K, Perrin, L, Vicaut, E, Lacreta, F, Hurbin, F, Dubar, M
• Format: Journal Article
• Language: English
• Published: United States 01.08.2011
• Subjects: Adenosine Diphosphate - pharmacology; Adult; Aryl Hydrocarbon Hydroxylases - genetics; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - pharmacokinetics; Platelet Aggregation Inhibitors - pharmacology; Polymorphism, Genetic; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacokinetics; Ticlopidine - pharmacology; Young Adult

A double-blind crossover study was conducted in four CYP2C19 genotype-defined metabolizer groups to assess whether increase in clopidogrel dosing can overcome reduced pharmacodynamic response in CYP2C19 poor metabolizers (PMs). Ten healthy subjects in each of four metabolizer groups were randomized...